期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不同类型乳腺组织中CD44^+/CD24^-细胞的数量与分布 被引量：3

Number and distribution of CD44^+/CD24^- cells in different type of breast tissues
下载PDF
导出
摘要 目的检测CD44+/CD24-细胞在乳腺正常组织及良恶性肿瘤中的数量与分布特点,探讨其在乳腺癌发生、发展中的作用。方法采用免疫组化SP双染法,检测了30例乳腺正常组织(normal tissue,NT),30例乳腺纤维腺瘤(fibroadenoma,FA),60例乳腺浸润性导管癌(invasive ductal carcinoma,IDC)中的CD44及CD24的共表达情况。结果在乳腺NT及FA中,可见CD44+/CD24+,CD44+/CD24-,CD44-/CD24-3种表型,而在IDC中,除上述3种表型外,尚可见CD44-/CD24+表型。从NT,FA到IDC,CD44+/CD24-细胞的阴性率(-,阳性率<1%)依次降低(40.0%→36.7%→35.0%);而强阳性率(▲,阳性率>60%)依次升高(0.0→6.7%→21.7%)。结论 CD44+/CD24-可能作为一种阶段性祖细胞标记,参与了正常乳腺的分化及乳腺肿瘤的发展过程。 Purpose To examine the quantity and the distribution of CD44＋/CD24-cells in breast normal tissue（NT）,fibroadenoma（FA）and invasive ductal carcinoma（IDC） and to investigate the function of the cells in breast carcinogenesis.Methods Double staining immunohistochemistry of CD44 and CD24 was performed on 30 cases of NTs,30 FAs,and 60 IDCs.Results In normal breast tissue and FAs,three phenotypes were observed including CD44＋/CD24＋,CD44＋/CD24-,and CD44-/CD24-.In the IDCs,CD44-/CD24＋ was detected beside the three aforementioned phenotypes.The proportions with lowest score（-,incidence 1%）of CD44＋/CD24-were decreased（40.0%→36.7%→35.0%）,but the proportions with highest score（▲,incidence 60%）of CD44＋/CD24-were increased（0.0→6.7%→21.7%）from normal breast tissue,FAs to IDCs.Conclusions The CD44＋/CD24-may be a marker for certain progenitor cells,which are involved in the differentiation of normal breast and the pathogenesis of breast tumors.
作者 吕新全 金湘东 吕会艳 徐珂佳 索振河 李惠翔
机构地区 郑州大学第一附属医院病理科/河南省肿瘤病理重点实验室 郑州铁路职业技术学院医学技术系 郑州大学第一附属医院肿瘤科
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2010年第5期536-539,共4页 Chinese Journal of Clinical and Experimental Pathology
基金 河南省基础与前沿技术研究计划项目(08230045460)
关键词 乳腺肿瘤 CD44 CD24 干细胞 breast tumor CD44 CD24 stem-like cell
分类号 R737.902.2 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Charafe-Jauffret E,Monville F,Ginestier C,et al.Cancer stem cells in breast:current opinion and future challenge[J].Pathobiology,2008,75(2):75-84.
  • 2Al-Hajj M,Wicha M S,Benito-Hernandez A,et al.Prospective identification of tumorigenic breast cancer cells[J].Proc Natl Acad Sci USA,2003,100(7):3983-8.
  • 3Dontu G.Breast cancer stem cell markers-the rocky road to clinical applications[J].Breast Cancer Res,2008,10(5):110.
  • 4Ponti D,Costa A,Zaffaroni N,et al.Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties[J].Cancer Res,2005,65(13):5506-11.
  • 5Phillips T M,McBride W H,Pajonk F.The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation[J].J Natl Cancer Inst,2006,98(24):1777-85.
  • 6Wright M H,Calcagno A M,Salcido C D,et al.Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics[J].Breast Cancer Res,2008,10(1):R10.
  • 7Mylona E,Giannopoulou I,Fasomytakis E,et al.The clinicopathologic and prognostic significance of CD44+/CD24(-/low)and CD44-/CD24+ tumor cells in invasive breast carcinomas[J].Hum Pathol,2008,39(7):1096-102.
  • 8Honeth G,Bendahl P O,Ringner M,et al.The CD44+/CD24-phenotype is enriched in basal-like breast tumors[J].Breast Cancer Res,2008,10(3):R53.
  • 9Abraham B K,Fritz P,McClellan M,et al.Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis[J].Clin Cancer Res,2005,11(3):1154-9.
  • 10Fogel M,Friederichs J,Zeller Y,et al.CD24 is a marker for human breast carcinoma[J].Cancer Lett,1999,143(1):87-94.

二级参考文献14

  • 1Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets[J].Proc Natl Acad Sci USA,2003,100(14):8418-23.
  • 2Page D L,Ellis I O,Elston C W.Histologic grading of breast cancer.Let's do it[J].Am J Clin Pathol,1995,103(2):123-4.
  • 3Nielsen T O,Hsu F D,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10(16):5367-74.
  • 4Van De Rijn M,Perou CM,Tibshirani R,et al.Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome[J].Am J Pathol,2002,161(6):1991-6.
  • 5Al-Hajj M,Wicha M S,Benito-Hernandez A,et al.Prospective identification of tumorigenic breast cancer cells[J].Proc Natl Acad Sci USA,2003,100(7):3983-8.
  • 6Liu R,Wang X,Chen G Y,et al.The prognostic role of a gene signature from tumorigenic breast-cancer cells[J].N Engl J Med,2007,356(3):217-26.
  • 7Abraham B K,Fritz P,McClellan M,et al.Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis[J].Clin Cancer Res,2005,11:1154-9.
  • 8Honeth G,Bendahl P O,Ringnér M,et al.The CD44+/CD24-phenotype is enriched in basal-like breast tumors[J].Breast Cancer Res,2008,10(3):53.
  • 9Mylona E,Giannopoulou I,Fasomytakis E,et al.The clinicopathologic and prognostic significance of CD44(+)/CD24(-/low) and CD44(-)/CD24(+) tumor cells in invasive breast carcinomas[J].Hum Pathol,2008,39(7):1096-102.
  • 10Perou C M,Sorlie T,Eisen M B,et al.Molecular portraits of human breast tumours[J].Nature,2000,406(6797):747-52.

共引文献7

同被引文献46

  • 1Cheng L, Alexander R, Zhang S, et al. The clinical and thera- peutic implications of cancer stem cell biology [ J ]. Expert Rev Anticancer Ther, 2011,11 ( 7 ) : 1133 - 45.
  • 2Florian I S, Tomuleasa C, Soritau O, et al. Cancer stem cells and malignant gliomas. From pathophysiology to targeted molecular therapy [ J ]. J BUON,2011,16 ( 1 ) : 16 - 23.
  • 3Lu X, Kang Y. Cell fusion hypothesis of the cancer stem cell [ J ]. Adv Exp Med Biol, 2011,714:129 -40.
  • 4Nguyen G H, Murph M M, Chang J Y. Cancer stem cell radiore- sistance and enrichment: where frontline radiation therapy may failin lung and esophageal cancers [ J ]. Cancers ( Basel ) , 2011,3 (1) :1232 -52.
  • 5Yang Y M, Chang J W. Bladder cancer initiating ceils (BCICs) are among EMA-CD44v6 + subset: novel methods for isolating un- determined cancer stem ( initiating ) cells [ J ]. Cancer Invest, 2008,26 (7) :725 - 33.
  • 6Dituri F, Mazzocca A, Lupo L, eds. PI3K class 1B controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma[ J]. Int J Cancer,2011,130( 11 ) :2505 - 13.
  • 7Buban T, Toth L, Tanyi M, et al. Ki-67--new faces of an old player [ J ]. Orv Heti1,2009,150 (23) : 1059 - 70.
  • 8Ishida T. Immunohistoehemical expression of the CD44 variant 6 in colorectal adenocarcinoma [ J ]. Surg Today,2000,30 ( 1 ) :28 - 32.
  • 9Haraguchi N, Ohkuma M, Sakashita H, et al. CD133 + CD44 + population efficiently enriches colon cancer initiating cells [ J ]. Ann Surg Oncol, 2008,15(10) :2927 -33.
  • 10Huang E H, Heidt D G, Li C W, et al. Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic re-sistanee [ J ]. Surgery,2007,141 (4) :415 - 9.

引证文献3

二级引证文献8

临床与实验病理学杂志
2010年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部